Assessing targetable NTRK1/2/3 fusions in mesenchymal tumors via whole-exome RNA sequencing
WERS reliably identifies actionable NTRK fusions, predominantly in five NMT subtypes, whereas NTRK fusions were rare and extremely rare in other sarcomas where their targetability remains unclear. Routine NTRK screening should prioritize tumors suspected of being NMT rather than being broadly applied.
Authors
- Sandrine Paindavoine
- M Karanian
- Nadège Corradini (ORCID: https://orcid.org/0000-0002-1942-1222)
- Hélène Vanacker
- Xiaolan Feng (ORCID: https://orcid.org/0000-0002-7333-8198)
- W. Waissi
- A. Meurgey
- Jean‐Yves Blay (ORCID: https://orcid.org/0000-0001-7190-120X)
- Aurélie Houlier
- Armelle Dufresne (ORCID: https://orcid.org/0000-0002-6637-3526)
- François Le Loarer (ORCID: https://orcid.org/0000-0001-8582-9819)
- Franck Tirode (ORCID: https://orcid.org/0000-0003-4731-7817)
- Isabelle Laure Ray-Coquard (ORCID: https://orcid.org/0000-0003-2472-8306)
- Mehdi Brahmi (ORCID: https://orcid.org/0000-0001-9904-166X)
- Daniel Pissaloux (ORCID: https://orcid.org/0000-0003-1118-950X)
Institutions
- University of Calgary (CA)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105555
- Citations
- 2
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.04